Exicure, Inc. (XCUR)
| Market Cap | 20.72M -61.2% |
| Revenue (ttm) | n/a |
| Net Income | -4.95M |
| EPS | -0.79 |
| Shares Out | 6.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,026 |
| Open | 3.245 |
| Previous Close | 3.240 |
| Day's Range | 3.230 - 3.440 |
| 52-Week Range | 3.101 - 11.860 |
| Beta | 4.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 25, 2026 |
About XCUR
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Financial Performance
Financial StatementsNews
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based bi...
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the follo...
Exicure, Inc. Reports Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant ...
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it w...
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial
Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive ...
Exicure, Inc. Reports Third Quarter 2025 Financial Results
REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended September 30, 2025.
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that resu...
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to sha...
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Developm...
Exicure, Inc. Reports Second Quarter 2025 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements.
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients.
Exicure, Inc. Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Q1 2025 earnings release.
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q.
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant.
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma.
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML).
Exicure, Inc. Reports Full Year 2024 Financial Results
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2024 Financial Results.
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Issuance of New Patent in Australia.
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc.
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Partners with GPCR Therapeutics Inc. to Fuel New Growth in Biotech.
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.